Lucid Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.55 Cr
as on 15-12-2024
- Paid Up Capital ₹ 2.10 Cr
as on 15-12-2024
- Company Age 21 Year, 1 Month
- Last Filing with ROC 31 Mar 2018
- Satisfied Charges ₹ 9.20 Cr
as on 15-12-2024
- Revenue %
(FY 2018)
- Profit 1129.48%
(FY 2018)
- Ebitda 25.65%
(FY 2018)
- Net Worth 1.77%
(FY 2018)
- Total Assets -1.80%
(FY 2018)
About Lucid Pharma
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 2.55 Cr and a paid-up capital of Rs 2.10 Cr.
The company has closed loans amounting to ₹9.20 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Vikram Rathore, Ummed Singh, and Kewal Dakalia serve as directors at the Company.
- CIN/LLPIN
U01400MH2003PTC142980
- Company No.
142980
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Nov 2003
- Date of AGM
29 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Lucid Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikram Rathore  | Director | 01-Sep-2014 | Current |
| Ummed Singh | Additional Director | 25-Apr-2019 | Current |
| Kewal Dakalia | Director | 06-Mar-2014 | Current |
Financial Performance and Corporate Structure Insights of Lucid Pharma.
Lucid Pharma Private Limited, for the financial year ended 2018, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 1129.48% increase in profit. The company's net worth moved up by a moderate rise of 1.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lucid Pharma?
In 2018, Lucid Pharma had a promoter holding of 36.76% and a public holding of 63.24%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of Maharashtra Creation Date: 26 Dec 2005 | ₹4.60 Cr | Satisfied |
Bank Of Maharashtra Creation Date: 21 Dec 2005 | ₹4.60 Cr | Satisfied |
How Many Employees Work at Lucid Pharma?
Unlock and access historical data on people associated with Lucid Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lucid Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lucid Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
